Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

NCT02564211 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Ipragliflozin
DRUG: Sitagliptin

Sponsor

Merck Sharp & Dohme LLC